Answers are grounded in this paper and cite their sources.
This first-time-in-human (FTIH) study evaluated the safety, tolerability, pharmacokinetics, and food effect of single and repeat oral doses of GSK3036656, a leucyl-tRNA synthetase inhibitor. In part A, GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg and placebo were administered. In part B, repeat doses of 5 and 15 mg and placebo were administered for 14 days once daily.
No takes yet. Share an insight, caveat, or question.
Tenero et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: